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We would like to comment on this article by Wil-
liam DuMouchel, as it gives an interesting applica-
tion of logistic regression to clinical safety data. Not
to underscore the scope of the multivariate Bayesian
logistic regression (MBLR) model, but the use of
numerical integration is arguably its most impor-
tant feature. Avoiding Markov chain Monte Carlo
(MCMC) sampling techniques for other data-mining
tools, such as the Multiple-item Gamma Poisson
Shrinker (DuMouchel, 1999), has proven successful
for Dr. DuMouchel in their acceptance among non-
statisticians. With MBLR this should not be an ex-
ception.
As most statisticians lack the clinical insight re-
quired to specify the appropriate MBLR model in-
puts, it makes MBLR an ideal tool for use by the
clinicians. However, targeted users may not appre-
ciate some subtleties of MBLR, which we present
below. We also present findings from our empirical
evaluation of the MBLR algorithm. This commen-
tary provides some perspective that we have gained
through multiple interactions with Dr. DuMouchel
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and from our reviews of different versions of MBLR
formulation at FDA since 2009.
1. MBLR AND META-ANALYSIS
In order to fully appreciate the MBLR methodol-
ogy, one has to contrast it with a more traditional
meta-analytical formulation when data from multi-
ple trials are investigated. Dr. DuMouchel is cor-
rect in pointing out that the MBLR methodology is
in the spirit of a full-data meta-analysis and does
not consider it a meta-analytic model. The current
MBLR model formulation does not render the flexi-
bility of separating out patient- and trial-level varia-
tions in the model. Consequently, MBLR is very dif-
ferent from a multi-level/meta-analysis model that
would consist of a patient-level model and a trial-
level model, each with independent sources of vari-
ation. This makes MBLR effectively a patient-level
model; the inclusion of trial-level variables (e.g., study
identifiers) into equation (2) results in the variance
components in equations (3)–(6) being influenced by
both patient and trial heterogeneity.
This distinction between the MBLR and its meta-
analytic formulation is critically important. The
main advantage of a meta-analytic formulation is
that it preserves the trial-specific randomized com-
parison between the treatment and control groups,
thereby avoiding confounded estimates. With the
MBLR formulation this is not necessarily the case,
as Dr. DuMouchel aptly notes for the Pollakiuria
example that the trial-specific estimates do not pre-
serve the between-trial differences. Additionally,
shrinkage estimates used to identify vulnerable pa-
tient subgroups depend on factors which are typi-
cally considered unrelated of patient characteristics.
The practical concern of applying a methodology
that does not ensure the randomized comparison is
preserved is that it may lead to a possible signal
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being missed or hidden. A recent high-profile exam-
ple of this concern was the meta-analysis of the di-
abetes drug rosiglitazone (Rucker and Schumacher,
2008). When safety data collected from the random-
ized controlled trials were pooled by trial arm, it
resulted in Simpson’s paradox.
It is, therefore, important to understand the sub-
tle distinction of how MBLR differs from the more
traditional meta-analytic models, and the potential
consequences that may arise from the use of MBLR.
Unfortunately, the MBLR tool/program in its cur-
rent capacity does not have the capability to evalu-
ate the potential implications discussed in the afore-
mentioned paragraphs. This necessitates the use of
other statistical methodologies to fully evaluate the
results from MBLR software, which, paradoxically,
is the situation that Dr. DuMouchel initially set out
to avoid. That said, it would be a nice extension if
the MBLR methodology was expanded, incorporat-
ing the suggestions outlined above, thereby increas-
ing the general utility of the tool. Next, we present
an attempt toward this extension.
2. META-ANALYTIC MBLR FORMULATION
We present a modified MBLR model motivated
from a meta-analytic perspective, which we shall,
henceforth, refer to as meta-analytic MBLR (MA-
MBLR). Using the notation from the paper, let the J
covariates correspond only to patient-level charac-
teristics and assume that there are a total of L trials.
Then, the MA-MBLR patient-level model for trial l,
l= 1, . . . ,L, and issue k is given by
logit(pikl) = α0kl +
∑
g
Xiglαgk
+ Til
(
β0kl +
∑
g
Xiglβgk
)
.
Unlike the MBLR formulation, the MA-MBLR would
assume the trial-specific intercept α0kl and treat-
ment effect β0kl have distinct variance components,
thereby separating patient and trial variability. This
can be formally achieved by assigning the trial-speci-
fic intercept and treatment effect of the following hi-
erarchical prior: α0kl∼N(α0k, σ
2
A.k) and β0kl∼N(β0k,
σ2
0.k), for k = 1, . . . ,K and l = 1, . . . ,L. The MA-
MBLR model is fully specified by equations (3)–(6),
as well as by the hyperpriors for the model’s hy-
perparameters, and has the (2K + 4) standard de-
viations, (σA.1, . . . , σA.K , σ0.1, . . . , σ0.K , σA, σ0, σB , τ),
that have independent uniform distribution on the
interval 0 to d, as specified in the paper.
We investigated for the data-example in the paper
whether the MBLR and MA-MBLR formulations
make a substantive impact on the risk assessment for
the five most frequent issues. Both the MBLR and
MA-MBLR models were fit using OpenBUGS (Lunn
et al., 2009), and thus are fully Bayesian MBLR and
MA-MBLR. The fully Bayesian models differed from
the MBLR model described in the paper in three
ways, namely, (i) it assumes diffused normal pri-
ors for the location parameters rather than uniform
noninformative priors, (ii) it constrains the hyper-
priors Ag such that the gjth level of covariate j is
equal to the negative sum of the remaining gj − 1
levels, and (iii) the support of the prior for the stan-
dard deviation d was increased to 3.
Figure 1 shows the relationship for some of the
estimated parameters. The issue specific treatment
effect β0k did not differ too much between mod-
els. However, the interaction term between treat-
ment and the patient-level covariates tended to be
closer to the null value for MA-MBLR, while the
MA-MBLR trial-specific treatment effect tended to
be further away from the null value than MBLR.
Although there were no surprising differences noted
between the MBLR and MA-MBLR coefficients for
this example, the two different formulations can pos-
sibly result in different substantive conclusions.
3. BORROWING INFORMATION ACROSS
ISSUES
It is important to note that MBLR borrows in-
formation across issues by positing a hierarchical
distribution to parameters from parallel logistic re-
gression models, and does not model the joint dis-
tribution of the endpoints. An example of the lat-
ter approach is given by Bayesian multivariate lo-
gistic regression (O’Brien and Dunson, 2004). More
importantly, there needs to be recognition among
its users that an analysis that borrows information
across issues is not inherently better than the one
that does not.
To illustrate a possible peril of borrowing infor-
mation across issues, suppose the issues selected are
medically related, but they vary in their severity;
in particular, assume there is one severe issue that
occurs infrequently and the remaining issues are less
severe but occur more frequently. Because the amount
of information borrowed across issues from MBLR
is related to the precision of the estimate (which is
a function of the issue frequency), the effect for the
less frequent issues would be sensitive to the effects
for the more frequent issues. It is important that
users of the tool are mindful of such considerations.
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Fig. 1. Relationship between MA-MBLR and MBLR for selected model parameters.
4. MBLR ESTIMATION ALGORITHM
As stated previously, we believe the advantage
of the MBLR methodology is in obtaining poste-
rior inferences that do not rely on computation-
ally time-consuming estimation methods (such as
MCMC methods). However, the timeliness of the
analysis has to be balanced by the well-known limi-
tations of the Laplace approximation of the integral
of the posterior density (Carlin and Louis, 2009),
which are applicable to MBLR.
As part of the software review at FDA, we evalu-
ated the adequacy of MBLR’s estimation algorithm
by contrasting results obtained from the fully Bayes-
ian MBLR using OpenBUGS; the comparison was
based on the data described in the paper. The fully
Bayesian MBLR differed from the MBLR by points (i)
and (ii) listed above. The two estimation approaches
yielded similar estimates for the variance compo-
nents ϕ= (σA, σ0, σB, τ) and the parameter estimates
had almost perfect correlation (ρ = 0.9998). How-
ever, the relationship based on z-scores (=estimate/
standard error), presented in Figure 2, suggests that
MBLR has smaller standard errors than the full
Bayesian analysis. This observation is also supported
by the simulation results, where MBLR tended to
have a type-I error rate that slightly exceeded the
nominal 10% level.
Fig. 2. Relationship of z-scores from fully Bayesian model fit using OpenBUGS compared to MBLR.
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5. CONCLUSION
The MBLR model will have a profound impact
as it is rolled-out being used for clinical safety data
analysis. However, in order to realize MBLR’s po-
tential strengths and pitfalls, it will require collabo-
ration between its different user-constituents, those
being statisticians and subject-matter experts.
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